Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
T Cell Non-Hodgkin Lymphoma
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Non-Hodgkin’s Lymphoma (1038
)
Diffuse Large B Cell Lymphoma (364
)
Mantle Cell Lymphoma (126
)
Small Lymphocytic Lymphoma (106
)
Follicular Lymphoma (85
)
Peripheral T-cell Lymphoma (71
)
Lymphoplasmacytic Lymphoma (64
)
Marginal Zone Lymphoma (41
)
Burkitt Lymphoma (20
)
Cutaneous T-cell Lymphoma (19
)
Mediastinal B Cell Lymphoma (10
)
Non-Hodgkin’s Lymphoma (1038
)
Diffuse Large B Cell Lymphoma (364
)
Mantle Cell Lymphoma (126
)
Small Lymphocytic Lymphoma (106
)
Follicular Lymphoma (85
)
Peripheral T-cell Lymphoma (71
)
Lymphoplasmacytic Lymphoma (64
)
Marginal Zone Lymphoma (41
)
Burkitt Lymphoma (20
)
Cutaneous T-cell Lymphoma (19
)
Mediastinal B Cell Lymphoma (10
)
›
Associations
(118)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
T Cell Non-Hodgkin Lymphoma
No biomarker
T Cell Non-Hodgkin Lymphoma
nelarabine
Sensitive: A1 - Approval
nelarabine
Sensitive
:
A1
nelarabine
Sensitive: A1 - Approval
nelarabine
Sensitive
:
A1
TNFRSF8 positive
Cutaneous T-cell Lymphoma
TNFRSF8 positive
Cutaneous T-cell Lymphoma
brentuximab vedotin
Sensitive: A1 - Approval
brentuximab vedotin
Sensitive
:
A1
brentuximab vedotin
Sensitive: A1 - Approval
brentuximab vedotin
Sensitive
:
A1
No biomarker
Cutaneous T-cell Lymphoma
No biomarker
Cutaneous T-cell Lymphoma
bexarotene oral
Sensitive: A1 - Approval
bexarotene oral
Sensitive
:
A1
bexarotene oral
Sensitive: A1 - Approval
bexarotene oral
Sensitive
:
A1
TNFRSF8 expression
Peripheral T-cell Lymphoma
TNFRSF8 expression
Peripheral T-cell Lymphoma
brentuximab vedotin
Sensitive: A1 - Approval
brentuximab vedotin
Sensitive
:
A1
brentuximab vedotin
Sensitive: A1 - Approval
brentuximab vedotin
Sensitive
:
A1
No biomarker
Peripheral T-cell Lymphoma
No biomarker
Peripheral T-cell Lymphoma
belinostat
Sensitive: A1 - Approval
belinostat
Sensitive
:
A1
belinostat
Sensitive: A1 - Approval
belinostat
Sensitive
:
A1
No biomarker
Peripheral T-cell Lymphoma
No biomarker
Peripheral T-cell Lymphoma
pralatrexate
Sensitive: A1 - Approval
pralatrexate
Sensitive
:
A1
pralatrexate
Sensitive: A1 - Approval
pralatrexate
Sensitive
:
A1
No biomarker
Peripheral T-cell Lymphoma
No biomarker
Peripheral T-cell Lymphoma
brentuximab vedotin
Sensitive: A1 - Approval
brentuximab vedotin
Sensitive
:
A1
brentuximab vedotin
Sensitive: A1 - Approval
brentuximab vedotin
Sensitive
:
A1
No biomarker
Cutaneous T-cell Lymphoma
No biomarker
Cutaneous T-cell Lymphoma
vorinostat
Sensitive: A1 - Approval
vorinostat
Sensitive
:
A1
vorinostat
Sensitive: A1 - Approval
vorinostat
Sensitive
:
A1
IL2RA expression
Cutaneous T-cell Lymphoma
IL2RA expression
Cutaneous T-cell Lymphoma
denileukin diftitox
Sensitive: A1 - Approval
denileukin diftitox
Sensitive
:
A1
denileukin diftitox
Sensitive: A1 - Approval
denileukin diftitox
Sensitive
:
A1
No biomarker
Peripheral T-cell Lymphoma
No biomarker
Peripheral T-cell Lymphoma
denileukin diftitox
Sensitive: A1 - Approval
denileukin diftitox
Sensitive
:
A1
denileukin diftitox
Sensitive: A1 - Approval
denileukin diftitox
Sensitive
:
A1
No biomarker
Cutaneous T-cell Lymphoma
No biomarker
Cutaneous T-cell Lymphoma
denileukin diftitox
Sensitive: A1 - Approval
denileukin diftitox
Sensitive
:
A1
denileukin diftitox
Sensitive: A1 - Approval
denileukin diftitox
Sensitive
:
A1
No biomarker
T Cell Non-Hodgkin Lymphoma
No biomarker
T Cell Non-Hodgkin Lymphoma
sugemalimab
Sensitive: A1 - Approval
sugemalimab
Sensitive
:
A1
sugemalimab
Sensitive: A1 - Approval
sugemalimab
Sensitive
:
A1
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.